On September 30, 2024, Mark Mortenson, Chief Science Officer of Clene Inc (CLNN, Financial), purchased 20,512 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now owns a total of 28,949 shares of Clene Inc.
Clene Inc is engaged in the development of unique therapeutic nanocatalysts. These nanocatalysts are designed to enhance cellular energy production, potentially offering novel treatments for various diseases with unmet medical needs.
The transaction occurred with shares priced at $4.75, valuing the purchase at approximately $97,434. This acquisition has contributed to a total of three insider buys over the past year, matching the number of insider sells during the same period.
The current market cap of Clene Inc stands at $29.763 million. According to the GF Value, the intrinsic value of the stock is estimated at $10.34, indicating a price-to-GF-Value ratio of 0.46. This suggests that the stock might be undervalued, warranting caution for potential investors.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the company's past performance and expected future business outcomes.
This insider buying activity could be a signal to investors about the insider's confidence in the future prospects of Clene Inc. However, potential investors should also consider the broader market conditions and other financial metrics before making investment decisions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
